Research programme: cancer immunotherapeutics adoptive ex vivo - GlaxoSmithKlineAlternative Names: Cancer adoptive immunotherapeutics - GlaxoSmithKline; Cancer adoptive immunotherapy - GlaxoSmithKline; Cancer immunotherapeutics - GlaxoSmithKline; ex vivo cancer immunotherapeutics - GlaxoSmithKline
Latest Information Update: 21 Jan 2008
At a glance
- Originator GlaxoSmithKline
- Mechanism of Action Immunomodulators; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Jan 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 20 Sep 1999 Preclinical development for Cancer in USA (Unknown route)